Research Papers:
The IGF1 receptor inhibitor picropodophyllin potentiates the antimyeloma activity of a BH3mimetic
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 3303 views | Full Text 3635 views
Liesbeth Bieghs1,2,3, Susanne Lub1, Karel Fostier1, Ken Maes1, Els Van Valckenborgh1, Eline Menu1, Hans E. Johnsen2, Michael T. Overgaard4, Olle Larsson5, Magnus Axelson6, Mette Nyegaard3, Rik Schots1, Helena Jernberg-Wiklund7, Karin Vanderkerken1,* and Elke De Bruyne1,*
1 Department of Hematology and Immunology-Myeloma Center Brussel, Vrije Universiteit Brussel, Brussels, Belgium
2 Department of Haematology, Aalborg Hospital, Aalborg University, Denmark
3 Department of Biomedicine, Aarhus University, Aarhus, Denmark
4 Department of Chemistry and Biotechnology, Aalborg University, Denmark
5 Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, Stockholm, Sweden
6 Department of Clinical Chemistry, Karolinska Hospital, Stockholm, Sweden
7 Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala, Sweden
* These are equal senior authors
Correspondence:
Elke De Bruyne, email:
Keywords: Multiple myeloma, IGF-1 receptor inhibitor, BH3-mimetic, preclinical study, mouse model
Received: February 26, 2014 Accepted: April 30, 2014 Published: April 30, 2014
Abstract
The ABT-analogous 737, 263 and 199 are BH3 mimetics showing potent anti-myeloma (MM) activity, but only on defined molecular subgroups of MM patients presenting a Bcl-2high/Mcl-1low profile. IGF-1 is a major survival factor in MM regulating the expression of Bcl-2 proteins and might therefore be a resistance factor to these ABT-analogous. We first show that IGF-1 protected human MM cell lines (HMCLs) against ABT-737. Concurrently, the IGF-1 receptor inhibitor picropodophyllin (PPP) synergistically sensitized HMCL, primary human MM and murine 5T33MM cells to ABT-737 and ABT-199 by further decreasing cell viability and enhancing apoptosis. Knockdown of Bcl-2 by shRNA protected MM cells to ABT-737, while Mcl-1 shRNA sensitized the cells. PPP overcame the Bcl-2 dependency of ABT-737, but failed to completely overcome the protective effect of Mcl-1. In vivo, co-treatment of 5T33MM bearing mice significantly decreased tumor burden and prolonged overall survival both in a prophylactic and therapeutic setting. Interestingly, proteasome inhibitor resistant CD138- 5T33MM cells were more sensitive to ABT-737, whereas PPP alone targeted the CD138+ cells more effectively. After co-treatment, both subpopulations were targeted equally. Together, the combination of an IGF-1R inhibitor and an ABT-analogue displays synergistic anti-myeloma activity providing the rational for further (pre)clinical testing.